SBM Offshore's Chief Executive Officer, Øivind Tangen confirmed that the upcoming Jaguar floating production storage and offloading vessel (FPSO) will be executed with the same team and expertise that handled the Liza Unity FPSO.
“We inherently bring all the learnings...
Hammerhead, Guyana’s 7th Stabroek Block development will be utilizing a converted unit for its floating, production, storage and offloading vessel (FPSO). This is according to ExxonMobil Guyana President, Alistair Routledge.
Hammerhead would be the first project after Liza Phase 1...
Guyana's Vice President Bharrat Jagdeo said Phase 2 of the Gas-to-Energy project can be completed in two years.
“We believe that is an outside limit,” he said during a press conference in Georgetown on September 26, following the publication...
ExxonMobil and its co-venturers, Hess and CNOOC, are set to add US$19 billion to their cost recovery bank, in addition to the approximately US$7 billion that remains to be recovered from existing investments in the prolific Stabroek Block offshore...
Authorities in Guyana are pursuing the second phase of a training facility in Berbice with support from ExxonMobil, slated for completion in 2025. The first phase, a simulator for floating production, storage and offloading (FPSO) vessels, was commissioned in...
The proposed Hammerhead development is set to create up to 1,380 jobs, preliminary estimates from ExxonMobil indicate.
The jobs span four stages of the project.
A project summary filed with the Environmental Protection Agency (EPA) indicates that approximately 540 persons would...
Guyana is set to welcome a trailblazing new floating production, storage and offloading (FPSO) vessel next year. The ONE GUYANA vessel, being constructed by SBM Offshore, is targeting the highest initial oil production observed in the industry for an...
In heavily pretreated patients with mycosis fungoides, treatment with lacutamab results in meaningful anti-tumor activity regardless of baseline KIR3DL2 expression level. Lacutamab was well-tolerated with a safety profile consistent with prior studies.
Innate will host a virtual KOL event on...
Agreement Adds to Shionogi’s Growing Pipeline in Rare Disease
MZE001 has the Potential to be the First Oral Therapy for Pompe Disease
OSAKA, Japan & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao...
New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates (DOR) at 12 months
PRINCETON, N.J--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers,...